WALTHAM, Mass., Oct. 7, 2013 /PRNewswire/ -- Those who treat people with type 2
diabetes know that making a conscious effort to change lifestyle habits shows
the best outcomes. Unfortunately, there are challenges to cutting intake of
foods with fat and refined sugar.
Before resorting to extreme measures, people with type 2 diabetes may want to
note the encouraging news coming out of Manchester, New Hampshire. The city is
home base of Boston Therapeutics, Inc., an innovative pharmaceutical company
working on complex carbohydrate compounds to help people concerned about blood
sugar moderate their blood glucose levels after eating carbohydrates.
The investigational treatment is a chewable tablet, locally acting complex
carbohydrate-based compound, PAZ320, a new chemical entity that is taken right
before a meal and designed to lower the rise of blood sugar that occurs after
eating. PAZ320 could prevent, or at least delay, the onset of type 2 diabetes
and a host of related complications ranging from heart disease to diabetic foot.
The compound works in the gut by blocking the action of carbohydrate hydrolyzing
enzymes that break down carbs in foods during digestion.
Researchers have already tested PAZ320 in patients with type 2 diabetes and
obtained positive results. In a study conducted at Dartmouth Medical Center, 45
percent of patients responded to PAZ320 with a significant 40 percent reduction
of post-meal glucose in the blood compared with the baseline. Additionally,
results showed the effect of PAZ320 works regardless of whatever other diabetes
medications one is taking. And there were no serious side effects.
A drug like PAZ320--even if approved for commercial use--is only one small tool
in the fight against diabetes. There are many other strategies to keep symptoms
at bay. But such a pill could provide another tactical weapon in the arsenal
against a problem whose incidence is exploding.
For more on this exciting advance, visit www.bostonti.com.
Contact: Susan Forman, Dian Griesel Int'l., 212.825.3210
SOURCE Boston Therapeutics, Inc.